文献速递慢阻肺

噻托溴铵/奥达特罗双支气管扩张剂较噻托溴铵单药进一步减少COPD活动相关呼吸困难

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD.
PubMed 文献 · Eur Respir J · 2019-03-28

本研究采用随机双盲两周期交叉设计,在中重度COPD伴肺过度充气且Mahler基线呼吸困难指数<8的患者中,比较噻托溴铵/奥达特罗5/5 µg与噻托溴铵5 µg治疗6周对3分钟恒速步行试验(CSST)后呼吸困难的影响;结果显示双支气管扩张剂在降低活动后Borg呼吸困难评分方面显著优于单药。

要点

  • 噻托溴铵/奥达特罗较噻托溴铵单药显著改善COPD患者活动相关呼吸困难。
  • 研究纳入中重度COPD伴静息肺过度充气且呼吸困难明显的患者。
  • 疗效评估采用3分钟恒速步行试验后Borg呼吸困难评分。

核心结论

  • 在中重度COPD伴肺过度充气且呼吸困难的病人中,噻托溴铵/奥达特罗比噻托溴铵单药更能减少活动相关呼吸困难。

研究设计与样本

  • 随机、双盲、两周期交叉研究,纳入中重度肺功能损害、静息肺过度充气且Mahler基线呼吸困难指数<8的COPD患者。
  • 患者按随机顺序接受6周噻托溴铵/奥达特罗5/5 µg与噻托溴铵5 µg治疗,洗脱期3周。
  • 3分钟CSST速度个体化设定,使完成试验时改良Borg量表呼吸不适强度≥4(「有些严重」)。

主要发现

  • 治疗6周后,3分钟CSST结束时Borg呼吸困难评分较基线下降:噻托溴铵组平均-0.968(95%CI -1.238至-0.698;n=100)。
  • 噻托溴铵/奥达特罗组3分钟CSST结束时Borg评分较基线平均下降-1.325(95%CI -1.594至-1.056;n=101)。
  • 噻托溴铵/奥达特罗对比噻托溴铵的呼吸困难改善组间差异为-0.357(95%CI -0.661至-0.053;p=0.0217),差异有统计学意义。

临床怎么用

  • 对于中重度COPD伴肺过度充气且活动后呼吸困难明显的患者,可考虑噻托溴铵/奥达特罗双支气管扩张剂以进一步改善活动相关呼吸困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 3-min constant speed shuttle test (CSST) was used to examine the effect of tiotropium/olodaterol compared with tiotropium at reducing activity-related breathlessness in patients with chronic obstructive pulmonary disease (COPD).This was a randomised, double-blind, two-period crossover study including COPD patients with moderate to severe pulmonary impairment, lung hyperinflation at rest and a Mahler Baseline Dyspnoea Index <8. Patients received 6 weeks of tiotropium/olodaterol 5/5 µg and tiotropium 5 µg in a randomised order with a 3-week washout period. The speed for the 3-min CSST was determined for each patient such that an intensity of breathing discomfort ≥4 ("somewhat severe") on the modified Borg scale was reached at the end of a completed 3-min CSST.After 6 weeks, there was a decrease in the intensity of breathlessness (Borg dyspnoea score) at the end of the 3-min CSST from baseline with both tiotropium (mean -0.968, 95% CI -1.238- -0.698; n=100) and tiotropium/olodaterol (mean -1.325, 95% CI -1.594- -1.056; n=101). The decrease in breathlessness was statistically significantly greater with tiotropium/olodaterol versus tiotropium (treatment difference -0.357, 95% CI -0.661- -0.053; p=0.0217).Tiotropium/olodaterol reduced activity-related breathlessness more than tiotropium in dyspnoeic patients with moderate to severe COPD exhibiting lung hyperinflation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maltais F, Aumann JL, Kirsten AM, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019. PMID: 30655277. doi:10.1183/13993003.02049-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。